Microcap Ledger Protara Therapeutics, Inc. $TARA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- Shares outstanding
- 59,095,488 [10-Q 2026-08-11]
What the company doesAI summary of filing
Protara Therapeutics is a clinical-stage biopharmaceutical company developing two investigational therapies. TARA-002 is a cell therapy based on OK-432, an immunopotentiating agent approved in Japan and Taiwan for lymphatic malformations and oncologic indications, which the company is developing for non-muscle invasive bladder cancer and lymphatic malformations in the United States and other territories. IV Choline Chloride is a phospholipid substrate replacement therapy in development for patients receiving parenteral support (nutrition and fluids), addressing a choline deficiency common in this population. The company is currently in clinical trials for both programs and has not generated any product revenues, with no near-term revenue expectations. [10-K 2026-03-10]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$39.45M | −$36.73M | $17.08M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$57.40M | −$56.37M | $49.66M | [DEF 14A 2026-04-28] |
| FY ended Dec 2024 | — | −$44.60M | −$35.81M | $162.80M | [DEF 14A 2026-04-28] |
- Quarterly cash burn
- −$18.37M
- Cash runway Estimate
- ~2.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 20,629,772 | [10-Q 2024-11-12] |
| 2025-02-28 | 36,767,465 | [10-K 2025-03-05] |
| 2025-05-01 | 38,581,863 | [10-Q 2025-05-08] |
| 2025-08-06 | 38,581,863 | [10-Q 2025-08-11] |
| 2025-11-06 | 38,587,260 | [10-Q 2025-11-10] |
| 2026-03-05 | 54,084,378 | [10-K 2026-03-10] |
| 2026-05-08 | 56,204,237 | [10-Q 2026-05-13] |
| 2026-08-07 | 59,095,488 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2026-05-14; declared effective 2026-05-22 [S-3 2026-05-14]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | Shefferman Jesse | other | 14,000 | — | [4 2026-07-01] |
| 2026-06-30 | Shefferman Jesse | other | 7,000 | — | [4 2026-07-01] |
| 2026-06-30 | Shefferman Jesse | other | 4,000 | — | [4 2026-07-01] |
| 2026-06-30 | Shefferman Jesse | other | 5,000 | — | [4 2026-07-01] |
| 2026-06-29 | Shefferman Jesse | exercise | 215,687 | $1.91 | [4 2026-07-01] |
| 2026-06-29 | Shefferman Jesse | sell | 215,687 | $4.09 | [4 2026-07-01] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-11 | 8-K | Results of operations |
| 2026-07-07 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-29 | 8-K | Director or officer change |
| 2026-06-15 | 8-K | Shareholder vote results |
| 2026-05-28 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | S-3 | Registration statement |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations |
| 2026-04-28 | DEF 14A | Proxy statement |
Alerts for $TARA
Email me when Protara Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.